在过度活跃膀综合征的先进治疗后进行治疗交叉
Preston Edge1, Lisa R Yanek2, Danielle Patterson1
1From the Departments of Gynecology and Obstetrics.
Urogynecology (Philadelphia, Pa.)
|January 22, 2025
概括
在先进的过活性膀疗法后,治疗交叉是不常见的. 皮肤穿神经刺激的治疗转换的可能性较高,与圣神经调节或OnabotulinumtoxinA相比. 药物使用在不同治疗方法之间有所不同.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医学经济学 医学经济学
背景情况:
- 过度活性膀综合征 (OAB) 影响了许多女性,当保守治疗失败时,先进疗法提供了替代方案.
- 选择神经神经调节 (SNM),内置突变器onabotulinumtoxinA (BTX-A) 和皮肤穿神经刺激 (PTNS) 之间需要考虑治疗的耐久性和随后的需求.
研究的目的:
- 为了估计先进OAB疗法之间的治疗交叉率.
- 为了比较在非神经性OAB的女性中SNM,BTX-A和PTNS之后的药物使用情况.
主要方法:
- 使用MarketScan索赔数据 (2013-2019) 的回顾性队列研究.
- 确定了接受指数先进治疗的OAB私人保险妇女 (18-65岁).
- 计算的比例的患者跨越到不同的先进疗法和那些使用OAB药物治疗后治疗.
主要成果:
- 在7231名女性中,4.3%的女性接受了另一种先进疗法.
- 在PTNS (8.0%) 后,交叉发生的可能性明显高于SNM (4.2%) 或BTX-A (2.6%).
- 在PTNS (29.2%) 后,治疗后使用药物的比例最高,而BTX-A (20.4%) 和SNM (18.8%) 则相比较高.
结论:
- 经过先进的OAB治疗后的治疗交叉是罕见的,但在PTNS时更常见.
- 相当少数患者在接受高级治疗后使用OAB药物,无论最初的治疗方法如何.
更多相关视频
相关概念视频
01:17Drugs for Treatment of Diarrhea-Predominant IBS
145
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
145
01:21Drugs for Treatment of Constipation-Predominant IBS
131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131